Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 11/20 | 0.45 |
| ▸ | CTSS | P25774 | 5/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL86157 | 1.00 | CA2 (0.53) | CA2CA1CA7CYP2D6CTSK | |
| SCHEMBL272661 | 1.00 | CA2 (0.53) | CA2CA1CA7CYP2D6CTSK | |
| Hydrochloric Acid SCHEMBL10594711 | 0.98 | CA2 (0.51) | CA2CA1CA7CYP2D6CTSK | |
| Hydrochloric Acid SCHEMBL29197256 | 0.98 | CA2 (0.51) | CA2CA1CA7CYP2D6CTSK | |
| Hydrochloric Acid SCHEMBL29408471 | 0.98 | CA2 (0.51) | CA2CA1CA7CYP2D6CTSK | |
| SCHEMBL12523040 | 0.85 | CA2 (0.47) | CA2CA1CA7CYP2D6CTSK | |
| SCHEMBL18196102 | 0.85 | CA2 (0.47) | CA2CA1CA7CYP2D6CTSK | |
| SCHEMBL86237 | 0.85 | CA1 (0.50) | CA2CA1CA7CYP2D6CTSK | |
| SCHEMBL86310 | 0.85 | CA1 (0.50) | CA2CA1CA7CYP2D6CTSK | |
| SCHEMBL1654201 | 0.85 | CA1 (0.50) | CA2CA1CA7CYP2D6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731631-A1 | BENZAMIDAZOLE DIAZAPINONE PARP INHIBITORS AND METHODS OF USE | Valo Health, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260070910-A1 | NITROGEN-CONTAINING HETEROCYCLIC AMIDE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2026-03-12 | — | — | US | disclosed |
| CN-120904124-B | Compound and preparation method and application thereof | 德阳悦合生物医药科技有限公司 | 2026-02-27 | — | — | CN | disclosed |
| CN-120904124-A | Compound and preparation method and application thereof | 德阳悦合生物医药科技有限公司 | 2025-11-07 | — | — | CN | disclosed |
| EP-4031542-B1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | MERCK SHARP & DOHME LLC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-12427146-B2 | C-terminal SRC kinase inhibitors | InventisBio Co., Ltd. (CN) | 2025-09-30 | — | — | US | disclosed |
| EP-4600247-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-12384797-B2 | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia | PTC THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250206744-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2025-06-26 | — | — | US | disclosed |
| EP-4570805-A1 | TRICYCLIC COMPOUNDS AND MEDICAL USE THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2025-06-18 | — | — | EP | disclosed |
| WO-2007008144-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF FACTOR XA | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| US-20060199851-A1 | Novel compounds that are useful for improving pharmacokinetics | ABBVIE INC. | 2006-09-07 | — | — | US | disclosed |
| US-20050250765-A1 | Diazepinones as antiviral agents | CHO HIDETSURA | 2005-11-10 | — | — | US | disclosed |
| EP-1590317-A1 | ENANTIOMER-PURE (4S,8S)- AND (4R, 8R)-4-P-NITROBENZYL-8-METHYL-3, 6, 9-TRIAZA- SP 3 /sp N, SP 6 /SP N, SP 9 /SP N-TRICARBOXYMETHYL-1, 11-UNDECANOIC ACID AND DERIVATIVES THEREOF, METHOD FOR PRODUCING THEM, AND THEIR USE FOR PRODUCING PHARMACEUTICAL AGENTS | Schering Aktiengesellschaft (DE) | 2005-11-02 | — | — | EP | disclosed |
| EP-1590005-A1 | CONJUGATES OF ENANTIOMER-PURE (4S,8S)- AND (4R,8R)-4-P-BENZYL-8-METHYL-3,6,9-TRIAZA- SP 3 /SP N, SP 6 /SP N, SP 9 /SP N-TRICARBOXYMETHYL-1,11-UNDECANOIC ACID WITH BIOMOLECULES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR PRODUCING PHARMACEUTICAL AGENTS | Schering Aktiengesellschaft (DE) | 2005-11-02 | — | — | EP | disclosed |
| US-20040208828-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic acid and derivatives thereof, process for their production and use for the production of pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-10-21 | — | — | US | disclosed |
| WO-2004069787-A1 | ENANTIOMER-PURE (4S,8S)- AND (4R, 8R)-4-P-NITROBENZYL-8-METHYL-3, 6, 9-TRIAZA-3N, 6N, 9N-TRICARBOXYMETHYL-1, 11-UNDECANOIC ACID AND DERIVATIVES THEREOF, METHOD FOR PRODUCING THEM, AND THEIR USE FOR PRODUCING PHARMACEUTICAL AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004069282-A1 | CONJUGATES OF ENANTIOMER-PURE (4S,8S)- AND (4R,8R)-4-P-BENZYL-8-METHYL-3,6,9-TRIAZA-3N,6N,9N-TRICARBOXYMETHYL-1,11-UNDECANOIC ACID WITH BIOMOLECULES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR PRODUCING PHARMACEUTICAL AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-08-19 | — | — | WO | disclosed |
| US-20040116410-A1 | Diazepinones as antiviral agents | CHO HIDETSURA (JP) | 2004-06-17 | — | — | US | disclosed |
| WO-2002014324-A2 | DIAZEPINONES AS ANTIVIRAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040208828-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic acid and derivatives thereof, process for their production and use for the production of pharmaceutical agents | CYP4B1, CYP2B6, UGT2B7 | CA2 1303/4885CA1 2549/4885CA7 130/4885 |
| US-12427146-B2 | C-terminal SRC kinase inhibitors | CSK, SRC, CSNK1G2 | CA2 3212/4885CA1 4224/4885CA7 3086/4885 |
| US-20060199851-A1 | Novel compounds that are useful for improving pharmacokinetics | CYP11B1, CYP11B2, CYP7A1 | CA2 953/4885CA1 1805/4885CA7 1603/4885 |
| US-20050250765-A1 | Diazepinones as antiviral agents | ZC3HAV1, ECI1, ZC3HAV1L | CA2 3287/4885CA1 2495/4885CA7 1623/4885 |
| US-12384797-B2 | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia | SF3B5, SF3B2, SF3B1 | CA2 4657/4885CA1 4838/4885CA7 4739/4885 |
| US-20250206744-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | IL17A, IL23R, IL15 | CA2 4099/4885CA1 4430/4885CA7 2443/4885 |
| US-20260070910-A1 | NITROGEN-CONTAINING HETEROCYCLIC AMIDE COMPOUND AND PHARMACEUTICAL USE THEREOF | PC, CS, IDH2 | CA2 410/4885CA1 534/4885CA7 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.